During aging, intracranial volume remains unchanged and represents maximally attained brain size, while various interacting biological phenomena lead to brain volume loss. Consequently, intracranial volume and brain volume in late life reflect different genetic influences. Our genome-wide association study (GWAS) in 8,175 community-dwelling elderly persons did not reveal any associations at genomewide significance (P < 5 × 10 −8 ) for brain volume. In contrast, intracranial volume was significantly associated with two loci: rs4273712 (P = 3.4 × 10 −11 ), a known height-associated locus on chromosome 6q22, and rs9915547 (P = 1.5 × 10 −12 ), localized to the inversion on chromosome 17q21. We replicated the associations of these loci with intracranial volume in a separate sample of 1,752 elderly persons (P = 1.1 × 10 −3 for 6q22 and 1.2 × 10 −3 for 17q21). Furthermore, we also found suggestive associations of the 17q21 locus with head circumference in 10,768 children (mean age of 14.5 months). Our data identify two loci associated with head size, with the inversion at 17q21 also likely to be involved in attaining maximal brain size.
During early development and maturation, brain growth is the major force for increasing intracranial volume 1, 2 . This process, which begins in utero, continues throughout childhood and ends in early adulthood, resulting in an intracranial volume that remains essentially unchanged throughout the remainder of life. During early life, intracranial volume is highly associated with brain volume. However, unlike intracranial volume, brain volume starts to decrease after early adulthood 3 . The greatest loss occurs in advanced age and is associated with disease states under polygenic and environmental influences, such as cerebrovascular and neurodegenerative diseases that result in brain atrophy 3, 4 . As a consequence, the degree of association between intracranial volume and brain volume declines with advancing age. Although intracranial volume and brain volume are both highly heritable 5, 6 , the genetic influences on these measures may differ.
To assess genetic features underlying these traits, we performed a GWAS on cross-sectional measures of intracranial volume and brain volume in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium 7 . This consortium brings together six population-based cohort studies, of which five participated in the current analysis 8, 9 : the Aging Gene-Environment SusceptibilityReykjavik Study (AGES-RS), the Atherosclerosis Risk in Communities Study (ARIC), the Austrian Stroke Prevention Study (ASPS), the Framingham Heart Study (FHS) and the Rotterdam Study (RS). The current report includes 8,175 persons of European descent, each with genome-wide genotype data and a quantitative measure of intracranial volume based on magnetic resonance imaging (MRI). For brain volume analysis, we excluded persons diagnosed with dementia or those who showed a cortical infarct on MRI. Moreover, brain volume was expressed as a percentage of intracranial volume to exclude genetic influences of intracranial volume on brain volume. The ASPS only had data available for brain volume and not for intracranial volume, resulting in a total of 8,673 persons in the current GWAS on brain volume ( Table 1) .
Data for replication came from a separate sample of 1,752 elderly subjects aged 66-96 years from AGES-RS, who had undergone MRI but Common variants at 6q22 and 17q21 are associated with intracranial volume l e t t e r s not genome-wide genotyping. Additionally, we investigated whether any of the loci significantly associated with intracranial volume or brain volume were also associated with head circumference in 10,768 children with an average age of 14.5 months from the Early Growth Genetics (EGG) Consortium 10 . Rather than being a formal replication, this analysis added support for association of the discovered loci with human brain development. Finally, because head size is a morphological phenotype related to adult height, we determined whether any significantly associated loci for intracranial volume were already implicated in height in a study by the Genetic Investigation of ANthropometric Traits (GIANT) Consortium 11 . We also performed additional height-adjusted analyses for the SNPs achieving genomewide significance. In addition, we examined the association with intracranial volume of all known loci for adult height.
Within the CHARGE Consortium, after quality control, each individual study imputed genome-wide genotype data to 2.2 million HapMap Utah residents of Northern and Western European ancestry (CEU) SNPs using automated software. Subsequently, each study performed genome-wide association tests for intracranial volume and brain volume using linear regression. Each study used the same basic additive genetic model of dosages of the risk allele with a 1-degreeof-freedom trend test, adjusting for age, sex and familial relationships (in FHS). For each study, we examined quantile-quantile plots for brain volume and intracranial volume to ensure that the P value distributions conformed to a null distribution, the expected distribution of P values if no genetic association was present, at all but the extreme tail (Supplementary Fig. 1 ). Finally, after performing genomic control in each study, we conducted meta-analysis on results across studies using inverse-variance weighting. Examination of the quantile-quantile plots from meta-analysis revealed an excess of extreme P values but no evidence of systematic inflation of the genomic control inflation factor (λ = 1.04 for intracranial volume and 1.02 for brain volume; Supplementary Fig. 2 ). The genome-wide plots of P values for the individual SNPs against their genomic position are shown (Fig. 1a,b) . We did not observe any association reaching genomewide significance for brain volume, although 46 SNPs reached P < 1 × 10 −5 (Supplementary Table 1 ). For intracranial volume, 720 SNPs located in two loci surpassed our preset threshold of genomewide significance (P < 5 × 10 −8 ). An additional 200 SNPs showed associations at P < 1 × 10 −5 (Supplementary Table 2 ).
The most significant association with intracranial volume was identified for rs9915547 on chromosome 17. The minor allele of this SNP (minor allele frequency (MAF) = 0.22) was significantly associated with smaller intracranial volume (P = 1.5 × 10 −12 ). This SNP belongs to an ~1-Mb large cluster of SNPs in very strong linkage disequilibrium (LD) with each other located in a region that has previously been identified as the chromosome 17q21 inversion (Fig. 2a) . The chromosome 17q21 inversion consists of two haplotypes (H1 and H2), with the minor allele of rs9915547 corresponding to the H2 haplotype. Adjusting for height did not change this result (P adjusted = 1.8 × 10 −12 ).
The second association at genome-wide significance was found for rs4273712 on chromosome 6q22, with RSPO3 and CENPW (also known as C6orf173) being the closest genes (Fig. 2b) . The minor allele of this SNP (MAF = 0.27) was associated with larger intracranial volume (P = 3.4 × 10 −11 ). This locus has previously been associated with adult height 11 . Of note, copy-number variations (CNVs) have been reported at this locus, with the closest CNVs to rs4273712 being described at positions 127,124,970-127,135,701 and 127,136,191-127,141,042. Both rs9915547 and rs4273712 were not associated with brain volume in our data (P = 0.23 and 0.67, respectively).
We sought to replicate the associations that were found at genomewide significance in a sample of 1,752 elderly persons (66-96 years old) from AGES-RS who were not included in the discovery sample. We genotyped rs4273712 and rs9303525 (P discovery = 1.6 × 10 −12 ), which maps to the inversion and is in perfect LD with rs9915547, and replicated association with intracranial volume at P = 1.1 × 10 −3 for rs4273712 and 1.2 × 10 −3 for rs9303525); the meta-meta-analysis of the replication sample with the discovery samples yielded P values of 1.8 × 10 −13 for the association with rs4273712 and 7.6 × 10 −15 for the association with rs9303525 ( Table 2) . 78 (4) 72 (4) 74 (4) 79 (4) 79 (4) 78 (4) 82 (3) 85 (3) a Values are reported for persons available for the brain volume GWAS. b Both the intracranial volume and brain volume analyses in AGES were performed after exclusion of persons with pathology or technical artifacts. 
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Finally, given the hypothesis that intracranial volume is reflective of maximum brain size during life, we reasoned that these loci may have a role in brain growth. Therefore, we investigated associations of these loci with head circumference in 10,768 children from the EGG Consortium 10 , in whom head circumference is much more likely to be a direct marker for brain growth than in adults 1 . We found that rs9915547 was significantly associated with head circumference (P = 5.3 × 10 −3 ). In the birth cohort studied, the most significant SNP within the 17q21 inversion was rs11655470, which was associated with head circumference at P = 1.4 × 10 −6 , although this SNP does not accurately map to the inversion itself (r 2 with the inversion = 0.22, based on HapMap CEU) 10 . Indeed, within the CHARGE Consortium, rs11655470 was only weakly associated with intracranial volume at P = 0.04. To investigate whether these signals were independent, we performed conditional analyses for rs9915547 and rs11655470 and found P = 6.3 × 10 −15 and 0.38, respectively. The attenuation in the significance of the association for rs11655470 suggests that the association is primarily driven by rs9915547, which maps to the inversion.
No association was found for rs4273712 with head circumference in the EGG Consortium (P = 0.16). Because rs4273712 is located in a known height-associated locus, we also determined the association with intracranial volume of all 180 known loci for adult height 11 (Supplementary Table 3 ). Outside of the 6q22 locus, only rs1351394 on chromosome 12 was associated with intracranial volume with nominal significance (P = 4.7 × 10 −6 ; threshold for Bonferroni-adjusted significance of 0.05/180 = 2.8 × 10 −4 ). Of note, another SNP at this locus (rs1042725) was associated with head circumference at genome-wide significance in the EGG Consortium (P = 2.8 × 10 −10 ) 10 . The r 2 value between the rs1042725 and rs1351394 SNPs was 0.91, based on the CEU sample in HapMap Phase 2.
Several genes are located in the 17q21 inversion, which is tagged by the H1 and H2 haplotypes. The two haplotypes show different expression patterns of these genes, some of which have been implicated in neurodegenerative disorders in late life, particularly in individuals with the H1 haplotype 12 . This region includes MAPT, which encodes the tau protein, a major hallmark of various dementias, including Alzheimer's disease and frontotemporal dementia [12] [13] [14] . Mutations in MAPT have been consistently associated with frontotemporal dementia, progressive supranuclear palsy and Parkinson's disease 15 . This region also includes GRN, which encodes progranulin, with mutations in this gene also capable of causing frontotemporal degeneration 16, 17 . Additional genes in the 17q21 inversion region include CRHR1 (encoding corticotrophin releasing hormone receptor 1), a gene that has been associated with early brain development and that might mediate the response to environmental stress 18 , and STH (encoding saitohin), which has been associated with increased risk of late-onset Alzheimer's disease and with progressive supranuclear palsy 14, 15 . In addition, smaller intracranial volume has been consistently associated with increased risk for late-life dementia 19 , suggesting that at least some of the findings related to intracranial volume and dementia risk may reflect the impact of this inversion on early development. 20, 21 .
The population genetics and evolutionary history of the 17q21 inversion are the object of ongoing research, with some studies suggesting that this inversion is approximately 3 million years old and almost exclusively present in the European population 22 , although more recent work contests this notion 23 . Moreover, findings that the H2 haplotype is undergoing positive selection in some European populations 22 have also recently been challenged, with an alternative explanation being proposed in which higher H2 frequency is considered a founder effect 23 . The influence of the inversion on brain development, as shown in our study, might be hypothesized to be one mechanism explaining the putative positive selection for the H2 haplotype. However, this explanation is unlikely, as the H2 haplotype is associated with smaller intracranial volume, whereas intracranial volume has increased throughout evolution from primates to Homo sapiens 24 . Still, our findings provide further insights into the role of the 17q21 inversion in human biology. More research is needed to determine its exact role.
Thus far, in order to explain our findings regarding 17q21, we have focused primarily on neurological mechanisms, assuming that brain growth drives intracranial volume. An alternative explanation is that variations in bone growth determine intracranial volume and, thus, maximum brain volume. However, given that the 17q21 inversion does not seem to influence height 11 and that height is particularly influenced by bone growth, this alternative explanation seems unlikely.
Two loci implicated in height were also associated with intracranial volume. This suggests the possibility of multiple functions for the loci on chromosomes 6 and 12 associated with brain development. rs4273712 on chromosome 6 is close to the RSPO3 gene, which encodes a protein of the thrombospondin type 1 repeat (TSR) superfamily, members of which seem to function in the development of the nervous system 25 . Another potentially relevant gene in this region is RNF146, which lies further downstream of RSPO3 and has been shown to be upregulated in brains from individuals with Alzheimer's disease 26 . We also note that reported CNVs could explain the association pattern seen at 6q22, as the region showed little recombination, but without any SNP being in clear LD with rs4273712.
The chromosome 12 locus maps to a gene that encodes a protein belonging to the non-histone chromosomal high-mobility group (HMG) protein family. This gene has been implicated in height, adipogenesis and mesenchymal differentiation. Although the association at this locus did not reach genome-wide significance with intracranial volume, it was associated at genome-wide significance with head circumference in children 10 . This further shows overlap in genetic variants that influence head size in childhood, maximum head size in adulthood and, possibly, brain growth.
In conclusion, our GWAS determined that the chromosome 17 inversion was strongly associated with intracranial volume. We further found that this inversion may have a role in brain growth in early life. A second association at genome-wide significance was found for rs4273712 on chromosome 6 near RSPO3 and RNF146, both of which potentially influence neuronal development and degeneration.
URLs. PLINK, http://pngu.mgh.harvard.edu/purcell/plink/; MaCH, http://www.sph.umich.edu/csg/abecasis/MACH/; R, http://r-project. org/.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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Participating cohorts. Analyses were performed among participants of studies in the CHARGE Consortium 7 . Details on the six participating discovery samples and the replication and extension samples can be found in the Supplementary Note. Each study has an Institutional Review Board that approved the consent procedures, examination components, data security processes, genotyping protocols and current study design. All participants gave written informed consent for study participation and for use of DNA for genetic research.
Measurement of intracranial volume and brain volume by MRI. Each study performed brain MRI on scanners ranging from 0.5 to 1.5 T in field strength. Each study used its own custom-made or freely downloadable fully automatic or semiquantitative MRI post-processing software to measure intracranial volume and brain volume. Brain volume was expressed as percentage of intracranial volume in order to correct for differences in individual head size in all studies. As a result of the software used, the ASPS only had measurements available for brain volume. All software has been extensively validated against manual tracings, which are the gold standard for automated MRI post-processing algorithms. We note that any remaining heterogeneity across studies due to differences in post-processing algorithms would lead to lower power; this in turn could lead to false negatives but would not invalidate the associations that were found. Genotyping, quality controls and imputation. The CHARGE consortium was formed after the individual studies had finalized their GWAS platforms, and the six studies included used different platforms, including the Illumina Human370-Duo BeadChip for AGES-RS, the Affymetrix GeneChip SNP Array 6.0 for ARIC; the Illumina Human610-Quad BeadChip for ASPS, the Affymetrix GeneChip Human Mapping 500K Array Set and 50K Human Gene Focused Panel for FHS and the Illumina HumanHap550 Duo BeadChip for RS.
As detailed previously 8, 9 , participant-specific quality controls included filters for call rate, heterozygosity and number of Mendelian errors per individual. SNP-specific quality controls included filters for call rate, MAF, HardyWeinberg equilibrium and differential missingness by outcome or genotype (mishap test in PLINK).
The set of genotyped input SNPs used for imputation in each study was selected on the basis of their highest quality data in the GWAS. We used SNPs with call rates of >95% in ARIC, >97% in FHS and >98% in AGES-RS, ASPS and RS; MAFs of >0.01 in each study; Hardy-Weinberg equilibrium P values of >1 × 10 −6 in AGES-RS, ARIC, ASPS, FHS and RS; and P values of >1 × 10 −9 in the test of differential missingness from the mishap test in PLINK in each study. We used the Markov Chain Haplotyping (MaCH) package (version 1.0.15 or 1.0.16) for AGES-RS, ARIC, ASPS, FHS and RS imputed to the plus strand of NCBI Build 36 using HapMap release 22. Imputation of genotypes provided a dosage value for every SNP between zero and two, indicating the expected value of a SNP being homozygous for the reference allele. For each imputed SNP, the informativeness of the imputation was estimated (as the ratio of the empirically observed dosage variance to the expected binomial dosage variance, O/E ratio). In the primary meta-analysis using inverse-variance weighting, less weight was given to imputed SNPs with low O/E ratios, resulting in higher variance of the estimate.
Studies were screened for latent population substructure 8, 9 , including cryptic relatedness, using suitable programs that included EIGENSTRAT 27 in ARIC, FHS and AGES-RS and an identity-by-descent (IBD) matrix in ASPS and RS. When appropriate, components related to intracranial volume or brain volume were included as covariates in linear regression.
We studied quantile-quantile plots to ensure that the P-value distributions in each of the cohorts conformed to a null distribution at all but the extreme tail.
We also calculated the genomic inflation factor λ, which measures overdispersion of test statistics from association tests, indicating population stratification, and can be used to apply genomic control.
Analysis within studies. Each study ran 1-degree-of-freedom additive association models of the GWAS with intracranial volume and brain volume. Alleles were used as dosages of 0, 1 or 2 copies of the risk allele. Intracranial volume was expressed in milliliters, whereas brain volume was expressed as percentage of intracranial volume to correct for individual head size differences. We note that the SIENAX software used in ASPS only provided this adjusted estimate of atrophy and no absolute volume in milliliters. All models were adjusted for age and sex and, in FHS, for familial relationships. In secondary analyses, we also adjusted for height.
Discovery meta-analysis. After quality control and filtering within each study, AGES-RS had either genotyped or imputed data for 2,408,992 SNPs, ARIC 2,298,221 SNPs, ASPS 2,317,924 SNPs, FHS 2,543,888 SNPs, RS I 2,543,888 SNPs, the RS II 2,543,888 SNPs and RS III 2,543,888 SNPs. We restricted the present meta-analysis to the 2,229,753 autosomal SNPs common to all studies. For our discovery meta-analysis, we used the technique of inverse-variance weighting, assuming fixed-effects, after applying genomic control within each individual study. β estimates were weighted by their inverse variance, and a combined estimate was obtained by summing the weighted β estimates and dividing by the summed weights. Hence results for SNPs imputed with low certainty were down-weighted, because low reliability of imputation ensures a large variance. In contrast, studies with large sample sizes and directly genotyped or well-imputed SNPs had greater effects on the meta-analyses P values because of small variances. We undertook the meta-analysis at Rotterdam using the R package MetABEL.
We estimated the genomic inflation factor λ after meta-analysis. The estimate of λ was 1.039 for intracranial volume and 1.019 for brain volume, indicating no significant inflation of P values. We also examined quantilequantile plots of the results from the meta-analysis. For intracranial volume, the original quantile-quantile plot was driven in large part by the chromosome 17 inversion and the numerous SNPs in close LD in that region; therefore, we recalculated the quantile-quantile plot after excluding the chromosome 17 inversion.
Replication analysis and extension analysis. The replication sample consisted of a random subset of 1,752 European participants from the AGES-RS, who had not undergone genome-wide genotyping at the time of the study but had MRI scans with measurement of intracranial volume available. Methods for measurement of intracranial volume were the same as for the rest of the participants from AGES-RS. Using TaqMan assays, we genotyped rs4273712 and rs9303535 (P discovery = 1.6 × 10 −12 ), which maps to the chromosome 17 inversion in perfect LD with rs9915547 (r 2 = 1 and D′ = 1 between these two SNPs). We performed 1-degree-of-freedom additive association relating these SNPs to intracranial volume. The threshold for statistical significance was set at P < 0.025 (Bonferroni correction for two SNPs). Subsequently, we performed meta-analysis on the results from the replication sample with those from the discovery sample using fixed-effect inverse-variance meta-analysis.
For extension of our samples, we examined loci that were associated with genome-wide significance in the discovery analysis in an existing meta-analysis on head circumference during infancy in 10,768 children (mean age of 14.5 months) 10 . In this analysis, the threshold for statistical significance was also set at P < 0.025. Head circumference was measured manually.
Association of reported height-associated loci with intracranial volume.
Because head size is a morphological phenotype related to adult height, we also examined all loci that were recently reported to be associated with adult height for their association with intracranial volume 11 . A total of 180 SNPs were tested, resulting in a Bonferroni-corrected P-value threshold of 0.05/180 = 2.8 × 10 −4 for significance. 
